Revanesse
Commercial- Indications
- Aesthetic medicine
Company intelligence / Profile preview
Prollenium’s flagship Revanesse line of hyaluronic acid dermal fillers has sold over four million syringes worldwide with FDA, Health Canada, and CE approvals. The company claims industry-leading safety profiles with low inflammation rates. Newer products are advancing into regenerative medicine approaches using exosomes, PDRN science, and collagen biostimulants for next-generation skin health solutions.[3][6][8]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Prollenium Medical Technologies.